Analysts Expect Genocea Biosciences Inc (NASDAQ:GNCA) to Announce -$0.41 Earnings Per Share

Analysts predict that Genocea Biosciences Inc (NASDAQ:GNCA) will post ($0.41) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Genocea Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.36). Genocea Biosciences posted earnings per share of ($0.88) in the same quarter last year, which would indicate a positive year over year growth rate of 53.4%. The company is scheduled to issue its next quarterly earnings results on Thursday, February 27th.

According to Zacks, analysts expect that Genocea Biosciences will report full-year earnings of ($2.00) per share for the current financial year, with EPS estimates ranging from ($2.13) to ($1.91). For the next fiscal year, analysts forecast that the business will report earnings of ($1.60) per share, with EPS estimates ranging from ($1.87) to ($1.12). Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover Genocea Biosciences.

Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Thursday, October 24th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.17.

A number of research analysts have commented on GNCA shares. Needham & Company LLC restated a “buy” rating and issued a $10.00 price objective on shares of Genocea Biosciences in a research note on Thursday, October 24th. ValuEngine cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday. HC Wainwright reiterated a “buy” rating on shares of Genocea Biosciences in a research note on Monday, November 11th. Svb Leerink began coverage on Genocea Biosciences in a report on Friday, November 15th. They set an “outperform” rating and a $7.00 price target on the stock. Finally, Leerink Swann assumed coverage on Genocea Biosciences in a research report on Friday, November 15th. They issued an “outperform” rating on the stock. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $12.94.

NASDAQ:GNCA traded down $0.12 during trading hours on Thursday, reaching $2.30. 655 shares of the company’s stock were exchanged, compared to its average volume of 146,535. Genocea Biosciences has a 1-year low of $1.99 and a 1-year high of $11.28. The company has a quick ratio of 4.33, a current ratio of 4.33 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $65.37 million, a price-to-earnings ratio of -0.63 and a beta of 2.42. The company has a 50-day moving average of $2.42 and a 200 day moving average of $3.30.

Several hedge funds and other institutional investors have recently modified their holdings of GNCA. FNY Investment Advisers LLC acquired a new position in shares of Genocea Biosciences during the second quarter worth about $526,000. Wedbush Securities Inc. acquired a new position in Genocea Biosciences during the 2nd quarter worth approximately $43,000. Wells Fargo & Company MN increased its position in Genocea Biosciences by 271.9% during the 2nd quarter. Wells Fargo & Company MN now owns 33,631 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 24,587 shares during the period. Monashee Investment Management LLC purchased a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $392,000. Finally, DRW Securities LLC purchased a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $118,000. 52.89% of the stock is owned by hedge funds and other institutional investors.

About Genocea Biosciences

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Featured Article: Earnings Reports

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.